- Human pathology

Home > A. Molecular pathology > CDs > CD37


Thursday 27 October 2016


- Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma (DLNCL). doi : 10.1182/blood-2016-05-715094

  • CD37 positivity predicts significantly better survival in DLBCL treated with R-CHOP, predominating other prognostic factors in GCB-DLBCL.
  • CD37 loss is a potent risk factor for R-CHOP resistance in both GCB- and ABC-DLBCL.